Genetic Study Reveals Why some Children Respond Better to Myopia Lenses

Genetic study reveals why some children respond better to myopia lenses

Myopia, or nearsightedness, has reached epidemic levels worldwide, particularly in East and Southeast Asia.

Why Do Some Kids Respond Better to Myopia Lenses? Genes Could Be the Key

A groundbreaking genetic study has uncovered new insights into why orthokeratology lenses, an innovative treatment increasingly used to slow the progression of myopia in children, work more effectively in some patients than others. This research, representing the largest genome-wide examination of its kind, reveals that the differential response to orthokeratology is linked to specific genetic variants associated with retinal function. The findi…

Why Some Kids Respond Better to Myopia Lenses? Genes Might Hold the Answer

New genetic research is shedding light on why some children benefit more than others from orthokeratology lenses--an increasingly popular method to slow the progression of myopia. In the largest genome-wide study of its kind, scientists discovered that children who responded better to treatment carried a higher number of nonsynonymous mutations in genes associated with retinal diseases. Among the key players identified were RIMS2 and LCA5, genes…

New Eye Implant Slows Retinal Degeneration

The FDA has approved ENCELTO, the first treatment for macular telangiectasia type 2 (MacTel), a rare degenerative eye disease that gradually impairs central vision. ENCELTO is a surgically implanted device that delivers a steady dose of a neuroprotective protein called CNTF to preserve retinal cells and slow disease progression.

Understanding macular degeneration - Cowra Guardian

Researchers share their tips for eye health

FDA Approves ENCELTO Implant as First Treatment for Macular Telangiectasia Type 2

The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Approves ENCELTO Implant as First Treatment for Macular Telangiectasia Type 2 first appeared on GeneOnline News. The post FDA Approves ENCELTO Implant as First Treatment for Macular Telangiectasia Type 2 appeared first on GeneOnline News.